What are the three main drivers Pfizer says will enable its return to growth after 2028?

Pfizer explicitly identifies three key drivers for its expected return to stronger growth after 2028: (1) obesity drugs in development — particularly its first candidate from the $10 billion Metsera acquisition, which would not reach the market before 2028; (2) a patent extension for its heart drug Vyndamax, secured through recent settlements with generic manufacturers that delay competition until mid-2031; and (3) a favorable European court ruling requiring Poland and Romania to accept €1.9 billion ($2.22 billion) worth of Pfizer-BioNTech COVID-19 vaccines.

Why did Pfizer maintain its full-year financial guidance despite beating Q1 earnings estimates?

Although Pfizer posted first-quarter adjusted profit of 75 cents per share — 3 cents above Wall Street estimates — and revenue of $14.45 billion (exceeding forecasts of $13.79 billion), it maintained its full-year revenue forecast of $59.5 billion to $62.5 billion and EPS guidance of $2.80 to $3.00, indicating management’s view that near-term outperformance does not yet alter the underlying trajectory shaped by looming patent expirations, fading COVID product sales, and the still-unproven clinical and commercial success of late-stage pipeline assets like its obesity drug.

Pfizer pins post 2028 return to growth on new obesity and cancer drugs

May 5, 2026

Pfizer forecasts post-2028 growth driven by new obesity and cancer drugs, beating Q1 revenue expectations despite declining COVID vaccine sales. Patent extensions for Vyndamax and a favorable EU court ruling further support its long-term financial outlook.

reuters

2026-05-05

Pfizer pins post 2028 return to growth on new obesity and cancer drugs

2026-06-24

Pfizer Dismissed from US States' Drug Price-Fixing Lawsuit

2026-08-04

Morning Bid: Earnings Overload

2026-08-28

13 Clinical Drug Candidates Unveiled at ACS Fall 2026 Meeting

Pfizer pins post 2028 return to growth on new obesity and cancer drugs

FAQ